NASDAQ · SMTI

Sanara MedTech Inc.

$25.85 +$0.29 (+1.13%) 1D After hours

Key Metrics

$234.23M
Market cap
P/E · TTM
$107.48M
Revenue · TTM
−$33.58M
Net income
EPS · TTM $-3.92
Dividend yield
Free cash flow $3.37M
Beta · 1Y 0.98
EBITDA · TTM $8.82M
Gross margin 92.9%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 12
    The stock moved +13.4% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 12
  • Mar 26
    The stock moved +10.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 26
  • Mar 25
    From its Feb 2 high, the share price fell 26%.

    Peak close $22.05 on Feb 2; trough close $16.34 on Mar 25. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -26%

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$234.23M
Enterprise value$252.70M
Shares outstanding9.2M
52-wk range$16.05 – $35.95
Avg volume · 20D26.6K
Net cash −$18.47M
Book value / share$0.82
IndustryOrthopedic, Prosthetic & Surgical Appliances & Supplies
ExchangeNASDAQ
About Sanara MedTech Inc.
IPO dateNov 2, 2020
Employees108

Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S2.18
P/FCF69.44
EV/EBITDA28.65
EV/Sales2.35
Graham №

Profitability

Gross 92.9%
Operating 4.0%
Net -31.2%
FCF 3.1%
ROE / ROIC -144.6% · —

Financial Health

Current ratio2.28
Quick ratio2.05
Debt / equity6.58
Debt / EBITDA 5.24
Net cash −$18.47M
Working capital$17.50M

Cash Flow · TTM

Operating CF $6.32M
Capex −$2.95M
Free cash flow $3.37M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

2.8
Grey zone (1.81–2.99) · monitor

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings